Fengcai Shen1, Qianpeng Han2, Di Xie3, Ming Fang4, Hongke Zeng5, Yiyu Deng6. 1. Department of Critical Care Medicine and Emergency, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China; Shantou University Medical College, Shantou, Guangdong, People's Republic of China. Electronic address: shenfengcai1111@126.com. 2. Department of Critical Care Medicine and Emergency, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China. Electronic address: hanqp@163.com. 3. Department of Critical Care Medicine and Emergency, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China. Electronic address: xdaspiwn@163.com. 4. Department of Critical Care Medicine and Emergency, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China. Electronic address: wellfm@163.com. 5. Department of Critical Care Medicine and Emergency, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China. Electronic address: zenghongke@vip.163.com. 6. Department of Critical Care Medicine and Emergency, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China. Electronic address: yiyudeng666@163.com.
Abstract
OBJECTIVES: To assess the efficacy and safety of tigecycline in comparison with other antimicrobial treatments for infectious diseases. DESIGN: Databases of PubMed, Embase and the Cochrane Library were searched through Feb. 2015. The reference lists of the initially identified articles and systemic review articles were manually searched. Randomized controlled trials assessing tigecycline and other antibiotics for infectious diseases in adult patients were included. RESULTS: Fifteen RCTs including 7689 cases were identified. We found that tigecycline was not as effective as the comparator agents for clinical treatment success (for the clinically evaluable population, odds ratio [OR] = 0.83, 95% confidence interval [CI] = (0.73, 0.96), P=0.01; for the clinically modified intent-to-treat (mITT) population, OR = 0.81, 95% CI = (0.72, 0.92), P=0.001). There was no significant difference in microbiological treatment success with lower eradication rate in tigecycline versus comparators (for the microbiologically evaluable population, OR = 0.94, 95% CI = (0.77, 1.16), P=0.56; for the microbiological mITT populations, OR = 0.91, 95% CI = (0.74, 1.11), P=0.35). Adverse events and all-cause mortality were more common in the tigecycline group. CONCLUSIONS: Tigecycline is not as effective as other antibiotics with relatively more frequency of adverse events and higher mortality rate.
OBJECTIVES: To assess the efficacy and safety of tigecycline in comparison with other antimicrobial treatments for infectious diseases. DESIGN: Databases of PubMed, Embase and the Cochrane Library were searched through Feb. 2015. The reference lists of the initially identified articles and systemic review articles were manually searched. Randomized controlled trials assessing tigecycline and other antibiotics for infectious diseases in adult patients were included. RESULTS: Fifteen RCTs including 7689 cases were identified. We found that tigecycline was not as effective as the comparator agents for clinical treatment success (for the clinically evaluable population, odds ratio [OR] = 0.83, 95% confidence interval [CI] = (0.73, 0.96), P=0.01; for the clinically modified intent-to-treat (mITT) population, OR = 0.81, 95% CI = (0.72, 0.92), P=0.001). There was no significant difference in microbiological treatment success with lower eradication rate in tigecycline versus comparators (for the microbiologically evaluable population, OR = 0.94, 95% CI = (0.77, 1.16), P=0.56; for the microbiological mITT populations, OR = 0.91, 95% CI = (0.74, 1.11), P=0.35). Adverse events and all-cause mortality were more common in the tigecycline group. CONCLUSIONS:Tigecycline is not as effective as other antibiotics with relatively more frequency of adverse events and higher mortality rate.
Authors: Nicholas A Turner; Batu K Sharma-Kuinkel; Stacey A Maskarinec; Emily M Eichenberger; Pratik P Shah; Manuela Carugati; Thomas L Holland; Vance G Fowler Journal: Nat Rev Microbiol Date: 2019-04 Impact factor: 60.633
Authors: Michael J Satlin; Liang Chen; Gopi Patel; Angela Gomez-Simmonds; Gregory Weston; Angela C Kim; Susan K Seo; Marnie E Rosenthal; Steven J Sperber; Stephen G Jenkins; Camille L Hamula; Anne-Catrin Uhlemann; Michael H Levi; Bettina C Fries; Yi-Wei Tang; Stefan Juretschko; Albert D Rojtman; Tao Hong; Barun Mathema; Michael R Jacobs; Thomas J Walsh; Robert A Bonomo; Barry N Kreiswirth Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: Andrei Nicoli Gebieluca Dabul; Juliana Sposto Avaca-Crusca; Daria Van Tyne; Michael S Gilmore; Ilana Lopes Baratella Cunha Camargo Journal: Microb Drug Resist Date: 2017-10-17 Impact factor: 3.431